S. pneumoniae remains one of the world’s most consequential bacterial pathogens, causing pneumonia and meningitis with the highest disease burden falling on young children and the elderly. When PCVs were first rolled out in the United States in 2000, they delivered striking reductions in disease and in carriage of the serotypes they target, which are defined by the bacterium’s capsular polysaccharide. But because the vaccines cover only a subset of the more than ninety known serotypes, they reshape competition within the species. Strains carrying non-targeted serotypes experience relaxed competition and can expand, replacing the vaccine types and eroding some of the public health gains.

Traditionally, pneumococcal epidemiology has been organised around serotypes, yet the capsular locus that defines them represents only a small slice of the species’ genetic diversity. Whole genome sequencing has revealed a far richer picture, including lineages called global pneumococcal sequence clusters (GPSCs), which are defined by variation across the entire genome. Because many GPSCs carry multiple serotypes, and individual serotypes appear in multiple GPSCs, the two classifications provide complementary information. Serotype replacement can therefore arise either from closely related strains switching capsule within a lineage or from genetically distant lineages expanding into the niche left open by vaccination.

A leading explanation for these dynamics is negative frequency-dependent selection, or NFDS, a form of selection in which a trait confers greater benefit when it is rare than when it is common. In bacteria, NFDS is thought to act on accessory genes such as antimicrobial resistance genes and bacteriocins, helping to maintain a diverse pangenome in which no single gene combination sweeps to fixation. Earlier modelling work, notably by Corander and colleagues in 2017, showed that NFDS could explain much of the post-vaccine reshuffling of pneumococcal populations, but those models were tightly coupled to specific datasets and difficult for non-specialists to redeploy.

The new study, led by Leonie Lorenz and John Lees of the European Molecular Biology Laboratory’s European Bioinformatics Institute together with collaborators across Nepal, the United Kingdom and Canada, addresses three gaps. First, the team rebuilt the population dynamics model in the odin modelling framework, separating model code, genomic inputs and fitting procedures so that public health bodies can adapt it to their own settings. Second, they tested whether cheaper data types, such as serotyping alone or targeted sequencing of a fixed gene set, could substitute for whole genome sequencing. Third, they used simulation to ask how sample size and sampling frequency affect the reliability of parameter estimates and forecasts.

The model itself is a compartmental extension of the Wright-Fisher framework, arranged on a two-dimensional grid in which one axis represents GPSC lineages and the other represents serotypes. Each generation, which corresponds roughly to a month of transmission, the population is replenished by offspring from the current generation plus immigrants drawn from an external reservoir of observed strain-serotype combinations. Four parameters are fitted to data by Markov chain Monte Carlo: vaccination effectiveness, the strength of NFDS, the proportion of intermediate-frequency genes subject to NFDS, and the immigration rate. Genes are summarised at the lineage level, and those changing least in frequency over time, ranked by a delta statistic, are flagged as candidates under balancing selection.

When fitted to carriage data from Kathmandu, where 1,881 samples were collected between 2009 and 2019 around the introduction of PCV10, and to previously published datasets from Massachusetts and Southampton, the model reproduced the observed serotype frequency changes closely, with model confidence intervals overlapping the data in nearly every case. Vaccination effectiveness estimates were consistent across all three locations, ranging from roughly 0.08 to 0.12 per generation, while immigration rates were similarly stable. Notably, the genes inferred to be under NFDS differed substantially between countries, and model comparison using likelihood-ratio tests and the Bayesian Information Criterion showed that only a subset of intermediate-frequency genes, not all of them, appear to be under NFDS. This suggests that other forces, such as balanced rates of gene gain and loss or ecological niche partitioning, also help maintain the accessory genome.

The search for a universal set of NFDS genes proved disappointing in an instructive way. A genetic algorithm applied to the same data found far more overlap between countries than the delta statistic did, yet even that shared set of 155 genes was no larger than expected by chance. Serotype-only model versions fit the data poorly. Together, these results indicate that neither serotyping nor targeted sequencing of a fixed gene panel can substitute for whole genome surveillance, underscoring that each country needs its own genomic monitoring programme to understand local replacement dynamics rather than importing conclusions from elsewhere.

The simulation experiments delivered the study’s most actionable finding. By generating a synthetic twenty-year dataset and then subsampling it under a fixed budget, the researchers showed that when resources are scarce, it is better to sample less often with larger samples per round. At the lowest budgets, annual and quadrennial sampling produced biased estimates, whereas biennial and triennial sampling performed best, balancing statistical power against the risk of missing critical change points. With larger budgets, sampling frequency mattered little. The team has released the model as an open-source R package called Stubentiger, giving surveillance agencies a practical tool for anticipating how pneumococcal populations will respond as vaccine formulations evolve.

Subject of Research: Mathematical modelling of negative frequency-dependent selection in the Streptococcus pneumoniae pangenome to inform genomic surveillance strategies during pneumococcal conjugate vaccine introduction

Article Title: A reusable model of pangenome selection informs optimal surveillance strategies over vaccine introductions

Article References: Lorenz, L. J., Hellewell, J., Horsfield, S. T., Russell, M. J., Shrestha, S., Pollard, A. J., Bentley, S. D., Lo, S. W., Colijn, C., Croucher, N. J., & Lees, J. A. (2026). A reusable model of pangenome selection informs optimal surveillance strategies over vaccine introductions. Genome Medicine, 18(1), Article 131. https://doi.org/10.1186/s13073-026-01672-4

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01672-4

Keywords: Streptococcus pneumoniae, pangenome, negative frequency-dependent selection, pneumococcal conjugate vaccine, serotype replacement, genomic surveillance, Wright-Fisher model, mathematical modelling, GPSC lineages, vaccine effectiveness, public health, Nepal

The trial was designed as a prospective, open-label, multicenter, active-controlled study conducted across 31 clinical sites in India, enrolling healthy infants who had never received a pneumococcal conjugate vaccine. Participants aged 6 to 8 weeks at enrollment received three primary doses of either BE-PCV14 or Prevenar 13, followed by a booster dose administered at 12 to 15 months of age, a regimen commonly described as a 3p plus 1 schedule. The investigators, led by Subhash Thuluva of Biological E Limited in Hyderabad, measured serotype-specific immunoglobulin G antibodies against all 14 vaccine serotypes as well as the cross-protective serotype 6A, assessed 28 days after the booster dose. The primary immunological benchmarks were seroresponse rates, defined as the proportion of children achieving serotype-specific IgG concentrations of at least 0.35 micrograms per milliliter, a threshold long used as a correlate of protection against invasive pneumococcal disease, along with geometric mean concentrations of antibody.

The immunogenicity analysis included 559 children who received BE-PCV14 and 147 who received PCV13, providing a substantial evidence base for the comparison. The results were striking in their consistency: after the booster dose, seroresponse rates with BE-PCV14 reached at least 92.8 percent for every one of the 14 vaccine serotypes, and climbed to 96.2 percent for serotype 6A, which is not itself in the vaccine but is known to elicit cross-protection through immunological relatedness to vaccine serotype 6B. For the serotypes shared between the two vaccines, the immune responses elicited by BE-PCV14 were comparable to those generated by Prevenar 13, and post hoc statistical analyses formally demonstrated non-inferiority for all 14 serotypes by both seroresponse and antibody concentration criteria.

The non-inferiority assessment deserves particular attention because of its methodological rigor. The investigators pre-specified that BE-PCV14 would be considered non-inferior to PCV13 for a given serotype if the lower bound of the 95 percent confidence interval for the difference in seroresponse rates exceeded minus 10 percent, and if the lower bound of the confidence interval for the ratio of geometric mean concentrations exceeded 0.5. These are the kinds of thresholds that regulators and vaccine advisory bodies use to judge whether a new product can reasonably substitute for an established one. BE-PCV14 cleared both hurdles for all 14 serotypes, a result that, in the words of the trial team, establishes the vaccine as a credible alternative within existing infant immunization schedules rather than an entirely new paradigm requiring altered dosing strategies.

Perhaps the most consequential finding involves serotypes 22F and 33F, the two additional strains incorporated into BE-PCV14 that are absent from PCV13. The vaccine induced strong antibody responses to both, with booster-induced increases in antibody concentration ranging from 2.4-fold to 5.3-fold across serotypes when compared with pre-booster levels. This matters because pneumococcal serotype replacement is a well-documented phenomenon: when a vaccine eliminates the strains it targets, other strains that were previously less common can expand to fill the ecological vacuum. Serotypes 22F and 33F have been increasingly recognized as causes of invasive pneumococcal disease in countries that have deployed PCV13 at scale, and their inclusion in a new vaccine represents a forward-looking strategy intended to stay ahead of shifting disease epidemiology rather than merely replicate existing coverage.

Safety data from the trial were equally reassuring. Adverse events occurred at similarly low frequencies in both vaccine groups and were predominantly mild local reactions, such as injection-site tenderness or redness, or transient fever. Only two serious adverse events were recorded among BE-PCV14 recipients, and the investigators judged neither to be related to vaccination. The safety profile through 28 days after the booster dose, therefore, mirrors the well-characterized tolerability of licensed pneumococcal conjugate vaccines, an essential consideration for a product intended for universal infant immunization in resource-constrained settings where health systems may have limited capacity to manage vaccine-associated complications.

The trial, registered prospectively with the Clinical Trials Registry of India under identifier CTRI/2023/09/057894 and approved by India’s Central Drugs Standard Control Organisation, was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent obtained from the parents or legally authorized representatives of all participants. Ethics committees overseeing each of the 31 participating sites granted approval, including the Institutional Ethics Committee of the All India Institute of Medical Sciences. The study, funded entirely by Biological E Limited, carries the inherent limitation that many of the authors are or were employees of the sponsoring company, though the trial’s active-controlled design against a licensed comparator and its prespecified statistical criteria provide meaningful safeguards against bias in the immunogenicity conclusions.

The public health significance of this work extends well beyond India’s borders. Streptococcus pneumoniae is responsible for hundreds of thousands of deaths among children under five each year, with the overwhelming majority occurring in low- and middle-income countries where access to effective vaccines has historically lagged behind wealthy nations. Pneumococcal conjugate vaccines have traditionally been among the most expensive components of childhood immunization schedules, and the introduction of a WHO-prequalified vaccine manufactured in a middle-income country carries the potential to lower prices, expand supply, and reduce dependence on a small number of multinational manufacturers. For India, which runs one of the largest immunization programs in the world through its Universal Immunization Programme, a domestically produced 14-valent vaccine that slots into the standard 3-plus-1 schedule offers both strategic and epidemiological advantages.

The trial’s findings also speak to a broader evolution in pneumococcal vaccine science. The 0.35 micrograms per milliliter IgG threshold used in this study is a population-level benchmark derived from efficacy trials of earlier conjugate vaccines, and while it does not guarantee individual protection, it remains the standard immunological bridge for licensure and comparison of new formulations. The demonstrated booster response, with antibody concentrations rising severalfold after the toddler dose, indicates that BE-PCV14 successfully exploits the immunological memory established during the primary series, an attribute that underpins the durability of protection in the second year of life, when the burden of invasive pneumococcal disease and pneumonia peaks in unvaccinated populations.

As pneumococcal disease patterns continue to shift under the selective pressure of global vaccination, the arrival of a well-tolerated, immunogenic 14-valent conjugate vaccine that extends coverage to emerging serotypes while matching the performance of the established 13-valent standard represents a meaningful advance. The authors conclude that PNEUBEVAX 14, when used as a booster in a 3-plus-1 schedule, is well tolerated and elicits robust responses comparable to PCV13 for shared serotypes while effectively broadening coverage to 15 serotypes when cross-protection against 6A is counted. For immunization programs weighing how to future-proof their pneumococcal strategies, this trial provides a substantial and encouraging body of evidence that broader serotype coverage need not come at the cost of safety or immunogenicity.

Subject of Research: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine in Indian infants and toddlers

Article Title: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

Article References: Thuluva, S., Gunneri, S., Ningaiah, S., Yerroju, V., Mogulla, R. R., Dhar, C., Thammireddy, K., Desai, S., Paliwal, P., Loka, C., Esanakarra, R., Narayandas, S., Chakravarthy, B. S., Narayan, J. P., Mahantshetti, N. S., Narang, M., Karayar, R. A., Verma, S., Thakkar, P. A., & Prabhakar, J. P. (2026). Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14412-1

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14412-1

Keywords: pneumococcal conjugate vaccine, PNEUBEVAX 14, BE-PCV14, PCV13, infant immunization, serotype 22F, serotype 33F, invasive pneumococcal disease, India, phase IV trial, booster vaccination, Streptococcus pneumoniae